The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study
2021 · Frontiers in Oncology · 17 citations
https://doi.org/10.3389/fonc.2021.663612
K
Keiko Tanimura
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
104
Papers
1.0K
Citations
13
h-index
18
i10-index
Keiko Tanimura is an academic researcher from Kyoto Prefectural University of Medicine. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Diagnosis and Treatment. The author has an h-index of 13, co-authored 89 publications.
ORCID: 0000-0002-7826-4466Papers by this author
worksTreatment rationale and design of the RAMNITA study
2018 · Medicine · 6 citations
https://doi.org/10.1097/md.0000000000011084
YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
2024 · Clinical Cancer Research · 5 citations
https://doi.org/10.1158/1078-0432.ccr-24-1762
Overlap of Sjögren's Syndrome and Immune-Mediated Necrotizing Myopathy With Interstitial Lung Disease: A Case Report
2024 · Cureus · 0 citations
https://doi.org/10.7759/cureus.70385
709P The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%
2024 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2024.10.742
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
2025 · Lung Cancer · 0 citations
https://doi.org/10.1016/j.lungcan.2025.108104
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat